Physician profile
Moshe Weiss
NPI 1083683163
$2,650.13
in general payments reported to CMS, 2019-2025
19 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $391 · 2021: $356 · 2022: $287 · 2023: $548 · 2024: $378 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,257.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $547.09 | 2019-2025 | Lupron Depot |
| Ascendis Pharma Endocrinology INC | $407.08 | 2022-2025 | Skytrofa |
| Amneal Pharmaceuticals LLC | $389.79 | 2019-2025 | Unithroid |
| Pfizer INC. | $264.26 | 2019-2025 | |
| Azurity Pharmaceuticals, INC. | $262.38 | 2023-2025 | Triptodur, Triptodur |
| Tolmar Pharmaceuticals, INC. | $149.86 | 2021-2022 | |
| Novo Nordisk INC | $142.05 | 2019-2023 | Sogroya, Norditropin |
| Tolmar, INC. | $80.91 | 2023-2024 | |
| Endo Pharmaceuticals INC. | $75.74 | 2019-2021 | |
| Endo USA, INC. | $64.11 | 2024-2025 | Supprelin |
| Alexion Pharmaceuticals, INC. | $52.78 | 2019-2021 | |
| Ibsa Pharma INC. | $41.24 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $36.58 | 2024 | |
| Insulet Corporation | $32.54 | 2019 | |
| Ferring Pharmaceuticals INC. | $22.55 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $22.39 | 2021 | |
| Eton Pharmaceuticals, INC. | $21.81 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $20.46 | 2019 | |
| Horizon Therapeutics Plc | $16.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moshe Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.